Ya A Pustynnikov

Mozhaiskaya Hospital, Mozhaisk, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does Ya A Pustynnikov research?

Ya A Pustynnikov studies the use of Revelise (alteplase), a medication used to dissolve blood clots that cause ischemic strokes, which occur when blood supply to the brain is blocked. This research specifically examines how well this treatment works in everyday medical practice, particularly looking at older patients and those with additional health conditions. By evaluating patient outcomes after treatment, Pustynnikov seeks to provide insights that can help improve care for individuals who have suffered from these strokes.

Key findings

  • In a study involving 2,202 patients, 49.9% had good outcomes at discharge after receiving Revelise for ischemic stroke.
  • The rate of good outcomes improved to 66.4% after 90 days post-treatment.
  • The results indicated that Revelise is effective in reducing stroke-related disabilities even among older patients and those with comorbidities.

Frequently asked questions

Does Dr. Pustynnikov study ischemic strokes?
Yes, Dr. Pustynnikov focuses on the treatment of ischemic strokes using the medication Revelise.
What treatments has Dr. Pustynnikov researched?
Dr. Pustynnikov has researched the use of thrombolytic therapy with Revelise for treating ischemic strokes.
Is Dr. Pustynnikov's work relevant to older stroke patients?
Yes, Dr. Pustynnikov's research includes older patients and demonstrates effective treatment outcomes for them.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.